BusinessGalectin Therapeutics to Present Clinical Data at The Liver Meeting® 2017 Demonstrating the Ability of Non-Invasive Test to Identify Clinically Significant Portal Hypertension in Patients with Compensated NASH CirrhosisBy Nasdaq OMXOct 20, 2017, 12:30 PM UTC
BusinessGalectin Therapeutics CEO Peter G. Traber, M.D. Named Chair of the Conference for NASH Summit Europe 2017By Nasdaq OMXSep 25, 2017, 12:30 PM UTC
BusinessGalectin Therapeutics launches the Liver Line, an online community and publication on liver health and liver diseaseBy Nasdaq OMXMay 3, 2017, 12:31 PM UTC
BusinessGalectin Therapeutics launches the Liver Line, an online community and publication on liver health and liver diseaseBy Nasdaq OMXMay 3, 2017, 12:31 PM UTC
BusinessGalectin Therapeutics Issues Statement Regarding GALTW and GALTUBy Nasdaq OMXMar 23, 2017, 12:30 PM UTC
BusinessSurefire Receives Regulatory Approval for Infusion Systems and Guiding Catheters in MexicoBy Nasdaq OMXMar 20, 2017, 10:00 AM UTC
BusinessClinical Data Shows Surefire Technology Achieved 79% Objective Response versus 37% Using a Standard Microcatheter in Treating Primary Liver CancerBy Nasdaq OMXMar 8, 2017, 11:00 AM UTC
BusinessSurefire Medical Launches New Flexion Guiding Catheter with Nitinol Tip for Better Shape Retention, Improved Back-up SupportBy Nasdaq OMXMar 6, 2017, 11:00 AM UTC
